登录 | 注册    关注公众号  
微信公众号
搜索
 >  Cell>PD-L1 >SCCHO-ATP077L

CHO/Human PD-L1 Stable Cell Line (Low Expression) Development Service

For research use only.

  1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
  2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
  3. Comprehensive application data to support assay development and validation
  4. Full tracible record, stringent quality control and validated cell passage stability
  5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
  6. Global commercial license assistance whenever regulatory filing is required

描述(Description)

The CHO/ Human PD-L1 Stable Cell Line was engineered to express full length human PD-L1 receptor (Gene ID: 29126), with different levels of PD-L1 expression (High, Medium, Low), which can be used to mimic cancer target cells with various PD-L1 expression levels. When co-cultured with Human 4-1BB HEK293 Reporter Cell and anti-human 4-1BB/PD-L1 BsAb, the anti-human 4-1BB/PD-L1 BsAb can be crosslinked, thereby strengthening 4-1BB pathway-activated luminescence.

应用说明(Application)

• Useful for cell-based PD-L1 binding assay

• Useful for PD-L1-mediated crosslinking in reporter gene assay

PD-L1 Assay Principles

生长特性(Growth Properties)

Adherent

筛选标记(Selection Marker)

Puromycin (2 μg/mL)

培养基(Complete Growth Medium)

F-12K+ 10% FBS

冻存液(Freeze Medium)

Serum-free cell cryopreservation medium

装量(Quantity)

1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium

存储(Storage)

Frozen in liquid nitrogen.

支原体检测(Mycoplasma Testing)

Negative

无菌检测(Sterility Testing)

Negative

使用说明(Instructions for Use)

See data sheet for detailed culturing and assay protocol.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

Receptor Assay

PD-L1 FACS

Expression analysis of human PD-L1 on CHO/ Human PD-L1 Stable Cell Line by FACS.
Cell surface staining using PE-labeled anti-human PD-L1 antibody was performed on CHO/Human PD-L1 Stable Cell Line with different expression levels: CHO/Human PD-L1 Stable Cell Line (Low Expression); CHO/Human PD-L1 Stable Cell Line (Medium Expression); CHO/Human PD-L1 Stable Cell Line (High Expression).

Protocol

如有相关细胞池需求请联系我们

 
评论(0)
 
ACRO质量管理体系
 
 

背景(Background)

Programmed cell death 1 ligand 1 (PDL1) is also known as B7-H, B7H1, MGC142294, MGC142296, PD-L1, PDCD1L1 and PDCD1LG1,which is a member of the growing B7 family of immune molecules and is involved in the regulation of cellular and humoral immune responses.PDL1 is a cell surface immunoglobulin superfamily with two Ig-like domains within the extracellular region and a short cytoplasmic domain. This protein is broadly expressed in the majority of peripheral tissues as well as hematopoietic cells. Interaction between PDL1 and its receptors belonging to the CD28 family of molecules provide both stimulatory and inhibitory signals in regulating T cell activation and tolerance. PDL1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression.

Limited Use&License Disclosure

BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.

  1. If the researcher is not willing to accept the terms of limited use of this cell line product, and the product is unused, ACRO will accept return of the unused product.
  2. Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for profit or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research.
  3. This cell line is neither intended for any animal or human therapeutic purposes nor for any direct human in vivo use . You have no right to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
  4. ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
  5. ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
  6. Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order.cn@acrobiosystems.com for further details.

 

前沿进展

Ultrasound-Responsive Nanobubbles for Breast Cancer: Synergistic Sonodynamic, Chemotherapy, and Immune Activation through the cGAS-STING Pathway
Pu, Huang, Gui et al
ACS Appl Mater Interfaces (2025)
Abstract: Breast cancer remains the leading cause of cancer-related deaths among women worldwide, necessitating more effective treatment strategies. Chemotherapy combined with immunotherapy is the first-line treatment for breast cancer, but it still suffers from limited therapeutic efficiency and serious side effects, which are usually due to the poor delivery efficiency, drug resistance of tumor cells, and immunosuppressive tumor microenvironment. This study explores the development of ultrasound-responsive nanobubbles (Ce6/PTX Nbs) for targeted imaging and sonoimmunotherapy in breast cancer treatment. By integrating sonodynamic therapy (SDT), chemotherapy, and immunotherapy, the nanobubbles aim to address challenges such as poor drug delivery, systemic toxicity, and immune suppression in conventional therapies. The nanobubbles, composed of sonosensitizer chlorin e6 (Ce6)-modified phospholipid and loaded with the chemotherapeutic agent paclitaxel (PTX) enhancing drug-loading capacity, are designed to precisely target tumor sites via cyclic-RGD peptides. Upon ultrasound activation, Ce6 induces reactive oxygen species (ROS), promoting immunogenic cell death (ICD), while PTX disrupts tumor cell mitosis, enhancing the immune response. The nanobubbles' ultrasound responsiveness facilitates real-time imaging and controlled drug release, maximizing therapeutic efficacy while minimizing side effects. Key findings demonstrate that Ce6/PTX Nbs significantly reduced tumor growth in a 4T1 breast cancer model, enhanced immune activation via the cGAS-STING pathway, and increased the infiltration of CD8+ T cells in both primary and distant tumors. In combination with anti-PD-L1 checkpoint inhibitors, the treatment achieved a substantial suppression of tumor metastasis. This innovative approach offers a highly targeted, effective, and minimally toxic breast cancer treatment with potential for clinical translation due to its dual imaging and therapeutic capabilities.
Immune checkpoint inhibitor-associated linear IgA bullous dermatosis with recalcitrant ocular involvement: a rare presentation
Saeed, Hosking, Grando
Skin Health Dis (2025) 5 (1), 53-55
Abstract: Programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) receptor inhibitors have become imperative in the treatment of advanced solid organ malignancies such as metastatic melanoma. With this disinhibition of certain immune responses to induce an antitumour response, numerous adverse events have been reported, many of which affect the skin. While rare, PD-1/PD-L1 inhibitor-associated severe cutaneous adverse reactions (SCARs) can cause significant morbidity and/or mortality. New SCARs are reported with increasing frequency as immune checkpoint inhibitors become more widely used. Here, we present a rare case of recalcitrant ocular linear IgA bullous dermatosis associated with a PD-1 inhibitor. Awareness of this entity will allow more rapid recognition and initiation of appropriate management and treatment, which would reduce the morbidity and/or mortality associated with these serious adverse reactions.© The Author(s) 2025. Published by Oxford University Press on behalf of British Association of Dermatologists.
Diagnosis, Prognosis, and Treatment of Triple-Negative Breast Cancer: A Review
Jie, Ma, Huang
Breast Cancer (Dove Med Press) (2025) 17, 265-274
Abstract: Triple-negative breast cancer (TNBC) has become the most aggressive and worst prognostic subtype of breast cancer due to the lack of estrogen receptor, progesterone receptor and HER2 expression. This article systematically reviews the progress in the diagnosis, prognosis and treatment of TNBC. In terms of diagnosis, imaging techniques (such as dynamic contrast-enhanced MRI and multimodality ultrasound) combined with histological and immunohistochemical detection (such as Ki-67, PD-L1 expression) can improve the early diagnosis rate; molecular markers (PIM-1, miR-522) and subtype classification (LAR, IM, BLIS, MES) provide the basis for accurate classification. Prognostic evaluation requires a combination of clinicopathologic features (tumor size, lymph node metastasis, tumor-to-stroma ratio), molecular characteristics (BRCA mutation, PD-L1 expression), and prognostic scoring systems. In treatment strategies, chemotherapy remains the basis, but efficacy and side effects need to be balanced; neoadjuvant chemotherapy can improve the pathological complete response rate, while molecular markers (such as circulating tumor cells) help predict efficacy. In terms of targeted therapy, PARP inhibitors are significantly effective in patients with BRCA mutations, and antibody drug conjugates (eg, sacituzumab govitecan) provide new options for chemoresistant patients. In immunotherapy, PD-1/PD-L1 inhibitors combined with chemotherapy significantly improved progression-free survival, especially for PD-L1-positive patients. Combined therapy, metabolic reprogramming, and individualized treatment strategies need to be further explored in the future to overcome the heterogeneity and treatment resistance of TNBC. This article emphasizes the key role of multidisciplinary collaboration and precision medicine in optimizing TNBC management and provides an important reference for clinical practice and research direction.© 2025 Jie et al.
PD-1/PD-L1 checkpoint inhibitor-induced encephalitis in patients with lung adenocarcinoma: a report of three cases
Ota, Terashima, Hamada et al
Oxf Med Case Reports (2025) 2025 (3), omae201
Abstract: Immune checkpoint inhibitor (ICI)-induced encephalitis is rare. We present three cases of encephalitis associated with ICIs in lung adenocarcinoma patients. These patients presented with a variety of symptoms, but one of the common symptoms for all patients was loss of consciousness. All patients responded well to steroid treatment and survived longer than one month after the onset of symptoms. These cases highlight the difficulties in diagnosing encephalitis based only on clinical information, and timely management is important to improve survival. Opportunistic infections also have to be ruled out to diagnose ICI-induced encephalitis especially when brain metastases co-exist.© The Author(s) 2025. Published by Oxford University Press.
Showing 1-4 of 33821 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
PD-L1靶点信息
英文全称:Programmed death-ligand 1
中文全称:程序性死亡配体1
种类:Homo sapiens
上市药物数量:11详情
临床药物数量:152详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定